Advertisement
Table 2 Outcomes of patients who discontinued prophylaxis before and after cd4 count increase to ≧200 cells/μl and patients who did not initiated prophylaxis for pneumocystosis
| Outcome | Primary prophylaxis | Secondary prophylaxis | No prophylaxis | ||||
|---|---|---|---|---|---|---|---|
| CD4 <200/μL | CD4 ≧200/μL | P value | CD4 <200/μL | CD4 ≧200/μL | P value | ||
| Patient number, n | 211 | 68 | 145 | 71 | 165 | ||
| New/recurrent episodes of PCP, n | 11 | 1 | 6 | 1 | 3 | ||
| Time from discontinuation of prophylaxis to PCP, median, M | 13.7 (2.2-92.4) | 74.5 | 22.8 (8.3-69.3) | -20.7 | |||
| CD4 count when new PCP developed, median, cells/μl | 33 (8-138) | 9 | 4 (1-40) | -13 | 5 (0-87) | ||
| Total observation duration, PY | 366 | 234 | 241 | 210 | 104 | ||
| Incidence of new/recurrent PCP, per 100 PY (95% CI) | 3.00 (1.26-4.76) | 0.43 (0.01-2.38) | 0.03 | 2.49 (0.91-5.42) | 0.48 (0.01-2.65) | 0.13 | 2.88 (0.59-8.43) |
| Episodes of bacterial infection, n | 53 | 13 | 21 | 7 | 22 | ||
| Incidence of bacterial infection, per 100 PY (95% CI) | 14.48 (10.85-18.94) | 5.56 (2.96-9.50) | <0.001 | 8.71 (5.39-13.32) | 3.33 (1.34-6.87) | 0.03 | 21.16 (13.35-32.03) |
| Episodes of parasitic infection, n | 2 | 0 | 2 | 0 | 2 | ||
| Incidence of parasitic infection, per 100 PY (95% CI) | 0.54 (0.07-1.97) | 0 | 0.83 (0.10-3.00) | 0 | 1.92 (0.23-6.95) | ||
| Death, n (%) | 23 (10.9) | 4 (5.9) | 0.35 | 8 (5.5) | 1 (1.4) | 0.28 | 22 (13.3) |
| Patients lost to follow-up, n (%) | 40 (19.0) | 7 (10.3) | 0.19 | 16 (11.0) | 8 (11.3) | 1 | 44 (26.6) |
